In the clinical setting, considering equivocals as positive may lead to reduced specificity for PrC (as compared to other cancers where either PSMA or AMACR may be positive), however this improves the chances for detection of PrC or other cancers in such patients who undergo follow‐up investigations. The gene discussed is FOLH1; the disease is cancer.